Tisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas
Annals of Hematology · 2026
DOI: 10.1007/s00277-026-06840-5 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Hematology, 2026. Verfasst von Ellen Obstfelder und 5 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany. Hauptthemen laut MEDLINE: Quality of Life, Patient Reported Outcome Measures, Lymphoma, Large B-Cell, Diffuse, Immunotherapy, Adoptive. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Jena.
Abstract (Originalsprache)
Chimeric Antigen Receptor (CAR) T-cell therapy is an established treatment for relapsed or refractory large B-cell lymphoma (rr LBCL). While clinical efficacy is well documented, data on health-related quality of life (HRQoL) remain limited. This study assessed HRQoL in rr LBCL patients with long-term remission after CAR T-cell therapy versus high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT). Twenty-eight consecutive rr LBCL patients in sustained remission were analyzed, with 15 receiving CAR T-cell therapy (tisagenlecleucel) and 13 undergoing HD-ASCT between 2019 and 2023. HRQoL was assessed using EQ-5D-5 L and PROMIS-29 questionnaires at 12 months and at a median of 36.8 months (range 15.7–57.2 months) post cellular therapy. Groups were compared for differences in HRQoL indices and domain scores. Median age was 63.5 (range 23–73) years. Twelve months post-treatment, CAR T-cell recipients reported significantly higher HRQoL scores than HD-ASCT patients (EQ-5D-5 L index value: 0.89 ± 0.11 vs. 0.72 ± 0.21; p = 0.015). Consistently, PROMIS-29 revealed clinically meaningful advantages in the CAR T-cell cohort across all seven categories. At later follow-up, EQ-5D-5 L index values converged (index-value 0.82 ± 0.22 vs. 0.7 ± 0.25; p = 0.2), whereas PROMIS-29 still indicated sustained benefit in five domains among CAR T-cell recipients. CAR T-cell therapy was associated with superior HRQoL in the first year compared to HD-ASCT. Although some differences diminished over time, CAR T-cell patients continued to experience better outcomes in several domains. These findings highlight clinical relevance of patient-reported outcome in rr LBCL, particularly in longitudinal surveys, and underscore the value of integrating patient-centered metrics into therapeutic decisions-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany.
- Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany.
- Klinik und Poliklinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie, Universitätsklinikum Leipzig, Leipzig, Germany.
- Comprehensive Cancer Center Central Germany, Campus Leipzig, Leipzig, Germany.
- Fraunhofer Institute for Celltherapy and Immunology, Leipzig, Germany.
- Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany. Farina.Eigendorff@med.uni-jena.de.
Förderung
- Universitätsklinikum Jena
Zitieren
APA
Obstfelder, E., Herrmann, J., Vučinić, V., Hochhaus, A., Schnetzke, U., & Eigendorff, F. (2026). Tisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas. Annals of Hematology. https://doi.org/10.1007/s00277-026-06840-5
Vancouver
Obstfelder E, Herrmann J, Vučinić V, Hochhaus A, Schnetzke U, Eigendorff F. Tisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas. Annals of Hematology. 2026. doi:10.1007/s00277-026-06840-5
BibTeX
@article{Obstfelder2026,
author = {Obstfelder, Ellen and Herrmann, Johannes and Vučinić, Vladan and Hochhaus, Andreas and Schnetzke, Ulf and Eigendorff, Farina},
title = {Tisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-06840-5}
}
EUVIMED